학술논문
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
Document Type
article
Author
Guillaume Marquis‐Gravel; Amanda Stebbins; Lisa M. Wruck; Matthew T. Roe; Mark B. Effron; Bradley G. Hammill; Jeff Whittle; Jeffrey J. VanWormer; Holly R. Robertson; Jacqueline D. Alikhaani; Sunil Kripalani; Peter M. Farrehi; Saket Girotra; Catherine P. Benziger; Tamar S. Polonsky; J. Greg Merritt; Kamal Gupta; Thomas E. McCormick; Kirk U. Knowlton; Sandeep K. Jain; Ajar Kochar; Russell L. Rothman; Robert A. Harrington; Adrian F. Hernandez; W. Schuyler Jones
Source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Subject
Language
English
ISSN
2047-9980
Abstract
Background In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to age in atherosclerotic cardiovascular disease. Methods and Results In the ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81 mg or 325 mg. The primary effectiveness end point was death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke. The primary safety end point was hospitalization for bleeding requiring transfusion. A total of 15 076 participants were randomized to aspirin 81 mg (n=7540) or 325 mg (n=7536) daily (median follow‐up: 26.2 months; interquartile range: 19.0–34.9 months). Median age was 67.6 years (interquartile range: 60.7–73.6 years). Among participants aged 0.05 for all). Conclusions Age does not modify the impact of aspirin dosing (81 mg or 325 mg daily) on clinical end points in secondary prevention of atherosclerotic cardiovascular disease.